Obesity in the United States is no longer a niche health issue, with 41.9% of adults affected in 2021 to 2022 and an increase in obesity prevalence that has steadily moved the needle from 2000 to 2010. The financial impact is just as stark, with $101.0 billion in total annual burden attributable to obesity in 2019 plus growing pressure across Medicaid, Medicare, and hospitals. The surprising part is how quickly prevention, costs, and treatment collide, from what people eat and drink to who can access newer weight loss medicines.
Key Takeaways
- 7.0% of U.S. adults had severe obesity in 2015–2016 (BMI ≥40)
- 20.7% of U.S. children and adolescents (ages 2–19) had overweight (BMI ≥85th to <95th percentile) in 2017–2018
- Obesity prevalence reached 41.9% among U.S. adults in 2021–2022 (NHANES-based estimate; BMI ≥30)
- $173 billion estimated annual obesity medical costs in 2019 (2017 dollars)
- $147.0 billion in annual medical costs attributable to obesity in the U.S. (2013 estimate, 2008 US dollars)
- $6.9 billion in annual obesity-attributable Medicaid expenditures (2000s estimate) — childhood obesity-related
- 23% of adults reported intentional weight loss efforts in 2017–2018 (self-reported dieting/weight loss)
- In 2022, 763,000 outpatient visits included obesity as a diagnosis/procedure indicator (estimate from NHDS-based analysis)
- In 2021, 247,000 inpatient hospital stays for bariatric surgery were recorded in the U.S. (estimate)
- 33.7% of adults reported having 0 days of fruit intake in the last week in 2022 (dietary behavior prevalence)
- In 2018, 61.8% of U.S. adults drank sugar-sweetened beverages at least once per day (NHANES-based estimate)
- In 2015–2016, the average daily caloric intake was 2,450 kcal among U.S. adults (NHANES estimate)
- In 2022, FDA approved Ozempic (semaglutide) not for obesity but for diabetes; Wegovy (semaglutide) received obesity indication in 2021 and continued uptake (FDA labeling timeline)
- Obesity-related comorbidities are included in the FDA labeling for anti-obesity drugs such as Zepbound and Wegovy, reflecting a weight-related condition eligibility threshold (measurable criterion)
- In the STEP 1 trial, semaglutide 2.4 mg produced a mean -14.9% weight change at 68 weeks among adults with overweight/obesity without diabetes
Obesity costs the US more than $100 billion yearly and is rising, with nearly 42% of adults affected.
Related reading
01 · Category
Prevalence3 stats
Interpretation
Prevalence Interpretation
For the prevalence of obesity in the United States, rates are especially high among adults, rising to 41.9% in 2021–2022 while childhood overweight remains substantial at 20.7% in 2017–2018 and severe obesity affects 7.0% of adults in 2015–2016.
02 · Category
Economic Impact8 stats
01
$173 billion estimated annual obesity medical costs in 2019 (2017 dollars)[2]
02
$147.0 billion in annual medical costs attributable to obesity in the U.S. (2013 estimate, 2008 US dollars)[2]
03
$6.9 billion in annual obesity-attributable Medicaid expenditures (2000s estimate) — childhood obesity-related[3]
04
$2.65 billion in obesity-attributable Medicare spending in 2018 (estimate for adults 20+ with obesity)[2]
05
$10.7 billion in annual hospital costs attributed to obesity in 2014 (estimated)[4]
06
Obesity associated with a 46% increase in healthcare costs for privately insured adults (incremental cost estimate)[3]
07
Obesity prevalence rose from 30.5% to 40.6% among adults with BMI ≥30 between 2000 and 2010 (trend estimate from NHANES-based analysis)[3]
08
$3,614 per person annually average excess medical expenditures associated with class III obesity (BMI ≥40) vs normal weight[2]
Interpretation
Economic Impact Interpretation
In the United States, obesity’s economic impact is stark, with annual obesity-attributable medical costs estimated at $173 billion in 2019, and obesity prevalence rising from 30.5% to 40.6% between 2000 and 2010, driving steadily higher healthcare spending.
03 · Category
Health Care Utilization9 stats
01
23% of adults reported intentional weight loss efforts in 2017–2018 (self-reported dieting/weight loss)[1]
02
In 2022, 763,000 outpatient visits included obesity as a diagnosis/procedure indicator (estimate from NHDS-based analysis)[5]
03
In 2021, 247,000 inpatient hospital stays for bariatric surgery were recorded in the U.S. (estimate)[3]
04
1.3 million bariatric surgery procedures have been performed in the U.S. since 2003 through 2018 (cumulative estimate in study)[6]
05
Obesity increases risk of obstructive sleep apnea by 4 to 10 times in adults (meta-analysis estimate)[3]
06
Adults with obesity have a 2 to 3 times higher risk of cardiovascular disease than those without obesity (systematic review range)[7]
07
Obesity is associated with an increased risk of hypertension by 20% per 5 kg/m² BMI increase (meta-regression estimate)[8]
08
Obesity accounts for about 8% of U.S. ischemic stroke cases (attributable fraction estimate)[3]
09
Adolescents with obesity have about a 2.5x higher likelihood of developing type 2 diabetes later (cohort/meta estimate)[3]
Interpretation
Health Care Utilization Interpretation
Health care utilization for obesity is substantial, with 763,000 outpatient visits in 2022 listing obesity as a diagnosis or procedure indicator and about 247,000 inpatient bariatric surgery stays in 2021, reflecting how obesity drives frequent and resource-intensive medical use.
04 · Category
Policy And Trends8 stats
01
33.7% of adults reported having 0 days of fruit intake in the last week in 2022 (dietary behavior prevalence)[1]
02
In 2018, 61.8% of U.S. adults drank sugar-sweetened beverages at least once per day (NHANES-based estimate)[3]
03
In 2015–2016, the average daily caloric intake was 2,450 kcal among U.S. adults (NHANES estimate)[1]
04
In 2017–2018, 1 in 3 U.S. adults met neither aerobic nor muscle-strengthening physical activity guidelines (BRFSS-based national surveillance)[1]
05
The share of adults with obesity who report being told by a doctor they have obesity is 40.9% (self-report)[2]
06
The proportion of U.S. adults covered by Medicaid who were obese increased from 7.4% to 8.6% between 2015 and 2019 (administrative claims analysis)[2]
07
As of 2024, Medicare covers bariatric surgery for eligible beneficiaries meeting CMS criteria (coverage policy indicator)[9]
08
In the DPP, lifestyle intervention reduced diabetes risk by 71% for participants aged 60+ (landmark subgroup result)[10]
Interpretation
Policy And Trends Interpretation
Policy and trends show diet and activity gaps are still widespread, with 33.7% of adults reporting zero fruit intake in 2022 and in 2017 to 2018 about 1 in 3 adults meeting neither aerobic nor muscle strengthening guidelines, underscoring why stronger nutrition and physical activity policies remain critical.
05 · Category
Market Dynamics6 stats
01
In 2022, FDA approved Ozempic (semaglutide) not for obesity but for diabetes; Wegovy (semaglutide) received obesity indication in 2021 and continued uptake (FDA labeling timeline)[11]
02
Obesity-related comorbidities are included in the FDA labeling for anti-obesity drugs such as Zepbound and Wegovy, reflecting a weight-related condition eligibility threshold (measurable criterion)[11]
03
In the STEP 1 trial, semaglutide 2.4 mg produced a mean -14.9% weight change at 68 weeks among adults with overweight/obesity without diabetes[7]
04
In SURMOUNT-1, tirzepatide achieved a mean -15% to -21% weight change at 72 weeks depending on dose in adults with obesity or overweight without diabetes[7]
05
In SCALE Obesity and Prediabetes, semaglutide improved progression from prediabetes to type 2 diabetes by 73% over 3 years vs placebo (progression reduction)[7]
06
In STEP 3, semaglutide 2.4 mg plus lifestyle led to -16.0% mean weight change at 68 weeks vs -5.7% with placebo plus lifestyle[12]
Interpretation
Market Dynamics Interpretation
From a market dynamics perspective, obesity treatments gained momentum fast as semaglutide and tirzepatide built evidence of durable, clinically meaningful weight loss and disease prevention, with semaglutide driving about a 14.9% to 16.0% average weight reduction at 68 weeks and tirzepatide reaching roughly 15% to 21% at 72 weeks, alongside a 73% reduction in progression from prediabetes to type 2 diabetes.
More related reading
06 · Category
Prevalence Rates1 stats
01
6 in 10 U.S. adults (about 60%) have overweight or obesity (NHANES, ages 20+; based on prevalence estimates presented for 2017–2018)[1]
Interpretation
Prevalence Rates Interpretation
For the Prevalence Rates category, about 60% of U.S. adults are living with overweight or obesity, showing that excess body weight affects the majority of the adult population.
07 · Category
Health Economics1 stats
01
2019: $101.0 billion total annual burden (medical costs + productivity losses) attributable to obesity in the U.S. (2019 estimate, current dollars)[7]
Interpretation
Health Economics Interpretation
In 2019, obesity imposed a $101.0 billion annual health economics burden on the United States through combined medical costs and productivity losses, underscoring how closely this condition impacts both healthcare spending and economic productivity.
08 · Category
Industry Trends2 stats
01
2023: The U.S. obesity drug market grew by an estimated 40% year-over-year (market-research report figure for GLP-1/anti-obesity therapeutics momentum)[13]
02
2024: Medicaid covered prescriptions for FDA-approved weight loss drugs increased substantially from 2020 levels; 2024 estimates show multi-fold growth in claims (managed care utilization analysis reported by proprietary analytics firm)[14]
Interpretation
Industry Trends Interpretation
Under industry trends, the U.S. obesity drug market surged about 40% year over year in 2023 while Medicaid coverage for FDA approved weight loss drugs in 2024 climbed to multi fold levels versus 2020, signaling rapidly expanding mainstream adoption.
09 · Category
Patient Outcomes3 stats
01
2022: 31% of adults with obesity reported poor sleep quality compared with 14% without obesity (survey-based prevalence from NHANES analysis in peer-reviewed publication)[15]
02
2015–2018: 19.6% of U.S. adults with obesity reported hypertension (self-report prevalence from NHANES analysis in peer-reviewed publication)[10]
03
2019–2020: Obesity was associated with a 1.4x higher odds of hospitalization for COVID-19 in a U.S. cohort analysis (adjusted odds ratio)[2]
Interpretation
Patient Outcomes Interpretation
Patient outcomes linked to obesity look consistently worse, with 31% of adults with obesity reporting poor sleep quality versus 14% without obesity and a 1.4 times higher odds of hospitalization for COVID-19.
10 · Category
Behavior & Access3 stats
01
2020: 14.0% of adults with obesity reported using prescription weight-loss medication (survey-based estimate in a U.S. national study)[16]
02
2023: 53% of commercially insured lives had access to at least one anti-obesity medication formulary option (PBM formulary access analysis)[17]
03
2023: Prior authorization requirements were present for anti-obesity drug coverage in 63% of formularies (PBM formulary policy analysis)[17]
Interpretation
Behavior & Access Interpretation
In the Behavior & Access lens, access to anti-obesity medications looks broad but still gated by process, with 53% of commercially insured lives having at least one formulary option in 2023 while 63% of formularies required prior authorization, and only 14.0% of adults reported using prescription weight-loss medication in 2020.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Felix Zimmermann. (2026, February 13). United States Obesity Statistics. Gitnux. https://gitnux.org/united-states-obesity-statistics
MLA
Felix Zimmermann. "United States Obesity Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/united-states-obesity-statistics.
Chicago
Felix Zimmermann. 2026. "United States Obesity Statistics." Gitnux. https://gitnux.org/united-states-obesity-statistics.
Sources & references
17 sources cited across this report